Signum grants GlaxoSmithKline exclusive, worldwide rights to Signum's phosphatase screening technology to identify compounds targeting protein phosphatase 2 (PPP2CA; PP2A)

Signum Biosciences Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

GlaxoSmithKline plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced